Recently, fourth-generation allosteric mutant-selective EGFR inhibitors have been developed that show synergistic anticancer effects against NSCLC with a mutant EGFR when combined with traditional EGFR inhibitors [32]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.